Inflammation pathway mediators

Inflammation pathway mediators is a collective term for a diverse group of molecules (including cytokines, chemokines, eicosanoids, vasoactive amines, and acute-phase proteins) that regulate all aspects of the inflammatory response[3][6][1][4]. These mediators are released by immune cells (such as macrophages, neutrophils, lymphocytes), damaged tissue, and plasma systems, and have roles in recruiting immune cells, modulating vascular permeability, regulating cytokine networks, mediating pain, and promoting tissue repair[6][4]. Because this term refers to a large mechanistic category, not a specific molecule or receptor, it cannot be used as a structured therapeutic target; individual mediators (e.g., TNF-α, interleukin-6, histamine, prostaglandins) are more correctly considered as direct drug targets. If your intent is to identify or select drug targets for inflammation, refer to specific mediators rather than the collective term[3][6][5]. This is not a valid molecular target name; instead, it is a descriptive category or functional grouping. Use with caution when database structuring or drug development.

Other names

Inflammatory mediatorsMediators of inflammationChemical mediators of inflammation

Inhibition of cytokine signaling; Blockade of eicosanoid synthesis (COX/LOX inhibitors); Inhibition of leukocyte migration/activation; Antagonism of specific receptors (e.g., TNF receptor, histamine receptor); Downregulation of inflammatory gene expression; Other